Relapsing Remitting Multiple Sclerosis Rrms clinical trials

Explore recruiting relapsing remitting multiple sclerosis rrms clinical trials.

Recruiting relapsing remitting multiple sclerosis rrms studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsing Remitting Multiple Sclerosis Rrms trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less than 18 Years for the Treatment of Relapsing Remitting Multiple Sclerosis, with Optional Open-Label Extension (105MS306)

Slovakia, Bulgaria, Hungary, Croatia, Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label, Parallel-Group Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizumab in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

Italy, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Multicenter, Phase Ib/IIa Study on the Safety and Efficacy of Autologous Peptide-coupled Red Blood Cells in Patients with Relapsing Remitting Multiple Sclerosis

Italy, Germany, Czechia

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

An Open-Label Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

Poland, Germany, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Open-Label, Randomized, Multicenter, Multi-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children from 10 to Less Than 18 Years of Age with Relapsing-Remitting Multiple Sclerosis with Optional Open-Label Extension (CONNECT)

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Relapsing Remitting Multiple Sclerosis Rrms trials by city

Relapsing Remitting Multiple Sclerosis Rrms in Toronto Relapsing Remitting Multiple Sclerosis Rrms in Vancouver Relapsing Remitting Multiple Sclerosis Rrms in Montreal Relapsing Remitting Multiple Sclerosis Rrms in Calgary Relapsing Remitting Multiple Sclerosis Rrms in Edmonton Relapsing Remitting Multiple Sclerosis Rrms in Ottawa Relapsing Remitting Multiple Sclerosis Rrms in Winnipeg Relapsing Remitting Multiple Sclerosis Rrms in Quebec City Relapsing Remitting Multiple Sclerosis Rrms in Hamilton Relapsing Remitting Multiple Sclerosis Rrms in Kitchener Relapsing Remitting Multiple Sclerosis Rrms in London Relapsing Remitting Multiple Sclerosis Rrms in Halifax Relapsing Remitting Multiple Sclerosis Rrms in New York Relapsing Remitting Multiple Sclerosis Rrms in Los Angeles Relapsing Remitting Multiple Sclerosis Rrms in Chicago Relapsing Remitting Multiple Sclerosis Rrms in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease